186 related articles for article (PubMed ID: 29603139)
1. A direct-to-patient telemedicine abortion service in Australia: Retrospective analysis of the first 18 months.
Hyland P; Raymond EG; Chong E
Aust N Z J Obstet Gynaecol; 2018 Jun; 58(3):335-340. PubMed ID: 29603139
[TBL] [Abstract][Full Text] [Related]
2. TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States.
Raymond E; Chong E; Winikoff B; Platais I; Mary M; Lotarevich T; Castillo PW; Kaneshiro B; Tschann M; Fontanilla T; Baldwin M; Schnyer A; Coplon L; Mathieu N; Bednarek P; Keady M; Priegue E
Contraception; 2019 Sep; 100(3):173-177. PubMed ID: 31170384
[TBL] [Abstract][Full Text] [Related]
3. Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic.
Chong E; Shochet T; Raymond E; Platais I; Anger HA; Raidoo S; Soon R; Grant MS; Haskell S; Tocce K; Baldwin MK; Boraas CM; Bednarek PH; Banks J; Coplon L; Thompson F; Priegue E; Winikoff B
Contraception; 2021 Jul; 104(1):43-48. PubMed ID: 33781762
[TBL] [Abstract][Full Text] [Related]
4. Client satisfaction and experience of telemedicine and home use of mifepristone and misoprostol for abortion up to 10 weeks' gestation at British Pregnancy Advisory Service: A cross-sectional evaluation.
Meurice ME; Whitehouse KC; Blaylock R; Chang JJ; Lohr PA
Contraception; 2021 Jul; 104(1):61-66. PubMed ID: 33974918
[TBL] [Abstract][Full Text] [Related]
5. [Medical abortion provided by telemedicine to women in Latin America: complications and their treatment].
Larrea S; Palència L; Perez G
Gac Sanit; 2015; 29(3):198-204. PubMed ID: 25770915
[TBL] [Abstract][Full Text] [Related]
6. Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland.
Aiken ARA; Digol I; Trussell J; Gomperts R
BMJ; 2017 May; 357():j2011. PubMed ID: 28512085
[No Abstract] [Full Text] [Related]
7. Regional differences in surgical intervention following medical termination of pregnancy provided by telemedicine.
Gomperts R; Petow SA; Jelinska K; Steen L; Gemzell-Danielsson K; Kleiverda G
Acta Obstet Gynecol Scand; 2012 Feb; 91(2):226-31. PubMed ID: 21950492
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of mifepristone-buccal misoprostol for early medical abortion in an Australian clinical setting.
Goldstone P; Walker C; Hawtin K
Aust N Z J Obstet Gynaecol; 2017 Jun; 57(3):366-371. PubMed ID: 28303569
[TBL] [Abstract][Full Text] [Related]
9. Women's experiences of a telemedicine abortion service (up to 12 weeks) implemented during the coronavirus (COVID-19) pandemic: a qualitative evaluation.
Boydell N; Reynolds-Wright JJ; Cameron ST; Harden J
BJOG; 2021 Oct; 128(11):1752-1761. PubMed ID: 34138505
[TBL] [Abstract][Full Text] [Related]
10. Provision of medical abortion by midlevel healthcare providers in Kyrgyzstan: testing an intervention to expand safe abortion services to underserved rural and periurban areas.
Johnson BR; Maksutova E; Boobekova A; Davletova A; Kazakbaeva C; Kondrateva Y; Landoulsi S; Lazdane G; Monolbaev K; Seuc Jo AH
Contraception; 2018 Feb; 97(2):160-166. PubMed ID: 29133110
[TBL] [Abstract][Full Text] [Related]
11. Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services.
Gomperts RJ; Jelinska K; Davies S; Gemzell-Danielsson K; Kleiverda G
BJOG; 2008 Aug; 115(9):1171-5; discussion 1175-8. PubMed ID: 18637010
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City.
Sanhueza Smith P; Peña M; Dzuba IG; García Martinez ML; Aranguré Peraza AG; Bousiéguez M; Shochet T; Winikoff B
Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):75-82. PubMed ID: 25702071
[TBL] [Abstract][Full Text] [Related]
13. Acceptability and feasibility of medical abortion with mifepristone and misoprostol in Nigeria.
Okonofua F; Shittu O; Shochet T; Diop A; Winikoff B
Int J Gynaecol Obstet; 2014 Apr; 125(1):49-52. PubMed ID: 24507887
[TBL] [Abstract][Full Text] [Related]
14. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.
Kopp Kallner H; Fiala C; Stephansson O; Gemzell-Danielsson K
Hum Reprod; 2010 May; 25(5):1153-7. PubMed ID: 20172871
[TBL] [Abstract][Full Text] [Related]
15. Acceptability and feasibility of 400 μg buccal misoprostol after 200 mg mifepristone for early medical abortion in Georgia.
Tsereteli T; Chong E; Louie K; Bokhua Z; Winikoff B
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):367-71. PubMed ID: 27449873
[TBL] [Abstract][Full Text] [Related]
16. Provision of medication abortion in Hawai'i during COVID-19: Practical experience with multiple care delivery models.
Kerestes C; Murayama S; Tyson J; Natavio M; Seamon E; Raidoo S; Lacar L; Bowen E; Soon R; Platais I; Kaneshiro B; Stowers P
Contraception; 2021 Jul; 104(1):49-53. PubMed ID: 33789080
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and acceptability of medical abortion provided through telemedicine.
Grossman D; Grindlay K; Buchacker T; Lane K; Blanchard K
Obstet Gynecol; 2011 Aug; 118(2 Pt 1):296-303. PubMed ID: 21775845
[TBL] [Abstract][Full Text] [Related]
18. At-home telemedicine for medical abortion in Australia: a qualitative study of patient experiences and recommendations.
Fix L; Seymour JW; Sandhu MV; Melville C; Mazza D; Thompson TA
BMJ Sex Reprod Health; 2020 Jul; 46(3):172-176. PubMed ID: 32665231
[TBL] [Abstract][Full Text] [Related]
19. Introducing medication abortion into public sector facilities in KwaZulu-Natal, South Africa: an operations research study.
Blanchard K; Lince-Deroche N; Fetters T; Devjee J; de Menezes ID; Trueman K; Sudhinaraset M; Nkonko E; Moodley J
Contraception; 2015 Oct; 92(4):330-8. PubMed ID: 26162575
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and acceptability of a mifepristone-misoprostol combined regimen for early induced abortion among women in Mexico City.
Peña M; Dzuba IG; Smith PS; Mendoza LJ; Bousiéguez M; Martínez ML; Polanco RR; Villalón AE; Winikoff B
Int J Gynaecol Obstet; 2014 Oct; 127(1):82-5. PubMed ID: 24957534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
